Noresmea (Norethisterone Acetate, Estradiol)

Norethisterone acetate and estradiol, the active ingredients in Noresmea, are an estrogen‑progestogen combination presented as an oral tablet for systemic use. They are used as a hormonal contraceptive to prevent pregnancy in women of reproductive age. The formulation provides both estrogenic and progestogenic activity, mimicking the natural menstrual cycle to inhibit ovulation. It is indicated for women seeking reliable, reversible birth control and is administered once daily in a 21‑day cycle followed by a hormone‑free interval. The product complies with EU regulatory standards for quality and safety.

GNH USA supplies Noresmea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Noresmea, a combined estrogen‑progestogen oral contraceptive, acts on the hypothalamic‑pituitary‑ovarian axis to prevent pregnancy and regulate menstrual function. - Contraception: provides reliable, reversible birth control for women of childbearing age. - Menstrual cycle regulation: helps achieve predictable monthly bleeding patterns. - Moderate acne treatment: reduces androgen‑driven skin lesions in women using hormonal contraception.

Common Side Effects: - Nausea: mild to moderate stomach upset, often transient. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: swelling or discomfort of the breasts. - Irregular bleeding: spotting or breakthrough bleeding between periods.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Stroke: cerebrovascular accident, particularly in high‑risk individuals. - Myocardial infarction: heart attack due to reduced coronary blood flow. - Severe allergic reaction: anaphylaxis, angioedema, or rash requiring urgent medical care.

Before initiating Noresmea, clinicians should evaluate individual risk factors and counsel patients on safe use. - Assess cardiovascular risk: avoid in women with a history of thromboembolic disease. - Screen for liver disease: contraindicated in active hepatic impairment. - Consider smoking status: not recommended for smokers over 35 years of age. - Review medication history: potential interactions with enzyme‑inducing drugs. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Noresmea may interact with several drug classes, requiring careful management. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce contraceptive efficacy. - Anticoagulants (e.g., warfarin): may alter anticoagulant effect and increase bleeding risk. - Certain antiretrovirals (e.g., efavirenz): decrease plasma hormone levels, compromising contraception. Moderate Interactions (Monitor Closely): - SSRIs (e.g., fluoxetine): can increase estrogen exposure, potentially heightening side‑effect risk. - Antihypertensives (e.g., beta‑blockers): may affect blood pressure control. - Thyroid hormones: hormonal contraception may necessitate adjustment of levothyroxine dose.